Cargando…

Are We Ready for Migrastatics?

Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solomon, Jonathan, Raškova, Magdalena, Rösel, Daniel, Brábek, Jan, Gil-Henn, Hava
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392519/ https://www.ncbi.nlm.nih.gov/pubmed/34440616 http://dx.doi.org/10.3390/cells10081845

Ejemplares similares

Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
por: Gandalovičová, Aneta, et al.
Publicado: (2017)

Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
por: Šuráňová, Markéta, et al.
Publicado: (2023)

Pragmatic medicine in solid cancer: a translational alternative to precision medicine
por: Brábek, Jan, et al.
Publicado: (2016)

Drugs for solid cancer: the productivity crisis prompts a rethink
por: Rösel, Daniel, et al.
Publicado: (2013)

Marine Migrastatics: A Comprehensive 2022 Update
por: Vasarri, Marzia, et al.
Publicado: (2022)

A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma
por: Maiques, Oscar, et al.
Publicado: (2021)

The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
por: Rašková, Magdalena, et al.
Publicado: (2022)

Are we ready to build health systems that consider the climate?
por: Mayhew, Susannah, et al.
Publicado: (2014)

Are We Ready to Implement Circadian Hygiene Interventions and Programs?
por: Moreno, Claudia R. C., et al.
Publicado: (2022)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

A Screen for PKN3 Substrates Reveals an Activating Phosphorylation of ARHGAP18
por: Dibus, Michal, et al.
Publicado: (2020)

Solid cancer: the new tumour spread endpoint opens novel opportunities
por: Fernandes, Michael, et al.
Publicado: (2019)

Investigation of anti-cancer and migrastatic properties of novel curcumin derivatives on breast and ovarian cancer cell lines
por: Koroth, Jinsha, et al.
Publicado: (2019)

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment
por: Strouhalova, Katerina, et al.
Publicado: (2020)

SH3 Domain Tyrosine Phosphorylation – Sites, Role and Evolution
por: Tatárová, Zuzana, et al.
Publicado: (2012)

Cell polarity signaling in the plasticity of cancer cell invasiveness
por: Gandalovičová, Aneta, et al.
Publicado: (2016)

Cytoplasmic Tail of MT1-MMP: A Hub of MT1-MMP Regulation and Function
por: Strouhalova, Katerina, et al.
Publicado: (2023)

Invasion and Metastasis as a Central Hallmark of Breast Cancer
por: Saha, Trishna, et al.
Publicado: (2021)

Self-directed learning in veterinary medicine: are the students ready?
por: Chigerwe, Munashe, et al.
Publicado: (2017)

Usnic Acid-Loaded Polymeric Micelles: An Optimal Migrastatic-Acting Formulation in Human SH-SY5Y Neuroblastoma Cells
por: Vasarri, Marzia, et al.
Publicado: (2022)

The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells
por: Paňková, K., et al.
Publicado: (2009)

The role of the tissue microenvironment in the regulation of cancer cell motility and invasion
por: Brábek, Jan, et al.
Publicado: (2010)

The interaction of p130Cas with PKN3 promotes malignant growth
por: Gemperle, Jakub, et al.
Publicado: (2018)

The emerging role of microtubules in invasion plasticity
por: Legátová, Anna, et al.
Publicado: (2023)

Evaluating Collaborative Readiness for Interdisciplinary Flood Research
por: Tate, Eric, et al.
Publicado: (2018)

Emergency preparedness and readiness; anticipating the need for rehabilitation
por: Skelton, Pete, et al.
Publicado: (2022)

High-throughput transcriptomic and proteomic profiling of mesenchymal-amoeboid transition in 3D collagen
por: Čermák, Vladimír, et al.
Publicado: (2020)

Site readiness practices for clinical trials – considerations for CTSA hubs
por: Viera, Laura, et al.
Publicado: (2023)

Are we ready?()
por: Pedrosa, C.
Publicado: (2020)

Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases
por: Saha, Trishna, et al.
Publicado: (2021)

A guide to simple, direct, and quantitative in vitro binding assays
por: Lapetina, Stefanie, et al.
Publicado: (2017)

FAK family kinases: The Yin and Yang of cancer cell invasiveness
por: Genna, Alessandro, et al.
Publicado: (2018)

Invadopodia Structure in 3D Environment Resolved by Near-Infrared Branding Protocol Combining Correlative Confocal and FIB-SEM Microscopy
por: Dalecká, Markéta, et al.
Publicado: (2021)

Sustained Inflammatory Signalling through Stat1/Stat2/IRF9 Is Associated with Amoeboid Phenotype of Melanoma Cells
por: Gandalovičová, Aneta, et al.
Publicado: (2020)

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
por: Zhou, Jun, et al.
Publicado: (2021)

The worst is not, so long as we can say “this is the worst”
por: Bate, Jonathan
Publicado: (2020)

Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?
por: Ashburner, Jeffrey M., et al.
Publicado: (2021)

Invasive cells in animals and plants: searching for LECA machineries in later eukaryotic life
por: Vaškovičová, Katarína, et al.
Publicado: (2013)

PKCα promotes the mesenchymal to amoeboid transition and increases cancer cell invasiveness
por: Vaškovičová, Katarína, et al.
Publicado: (2015)

Quantitative phase imaging unravels new insight into dynamics of mesenchymal and amoeboid cancer cell invasion
por: Tolde, Ondřej, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bcs86lj3r25qjmc5keb0clgqvn